Construction and Analysis of the Protein-Protein Interaction Networks Based on Gene Expression Profiles of Parkinson’s Disease

Hindol Rakshit¹, Nitin Rathi², Debjani Roy³

¹ Integrated Science Education & Research Centre (ISERC), Visva-Bharati University, Shantiniketan, Birbhum, West Bengal, India, ² Cognizant Technology Solutions India Pvt. Ltd., Rajiv Gandhi Infotech Park, MIDC, Hinjewadi, Pune, Maharashtra, India, ³ Department of Biophysics, Bose Institute, Acharya J.C. Bose Centenary Building, Kolkata, West Bengal, India

Abstract

Background: Parkinson’s Disease (PD) is one of the most prevailing neurodegenerative diseases. Improving diagnoses and treatments of this disease is essential, as currently there exists no cure for this disease. Microarray and proteomics data have revealed abnormal expression of several genes and proteins responsible for PD. Nevertheless, few studies have been reported involving PD-specific protein-protein interactions.

Results: Microarray based gene expression data and protein-protein interaction (PPI) databases were combined to construct the PPI networks of differentially expressed (DE) genes in post mortem brain tissue samples of patients with Parkinson’s disease. Samples were collected from the substantia nigra and the frontal cerebral cortex. From the microarray data, two sets of DE genes were selected by 2-tailed t-tests and Significance Analysis of Microarrays (SAM), run separately to construct two Query-Query PPI (QQPPI) networks. Several topological properties of these networks were studied. Nodes with High Connectivity (hubs) and High Betweenness Low Connectivity (bottlenecks) were identified to be the most significant nodes of the networks. Three and four-cliques were identified in the QQPPI networks. These cliques contain most of the topologically significant nodes of the networks which form core functional modules consisting of tightly knitted sub-networks. Hitherto unreported 37 PD disease markers were identified based on their topological significance in the networks. Of these 37 markers, eight were significantly involved in the core functional modules and showed significant change in co-expression levels. Four (ARRB2, STX1A, TFRC and MARCKS) out of the 37 markers were found to be associated with several neurotransmitters including dopamine.

Conclusion: This study represents a novel investigation of the PPI networks for PD, a complex disease. 37 proteins identified in our study can be considered as PD network biomarkers. These network biomarkers may provide as potential therapeutic targets for PD applications development.

Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder of the central nervous system. It is the second most common degenerative disorder after Alzheimer’s disease, affecting more than 1% of those over the age of 55 years and more than 3% of those over the age of 75 years [1]. PD is characterized by tremor, muscle rigidity, and slowed movement (bradykinesia). The motor symptoms of PD result from the death of dopamine generating cells in the substantia nigra, a region of the mid brain. Improving diagnoses and treatment of this disease is essential, as currently there exists no cure for PD.

For a long time, PD has been considered to be a non-genetic disorder; however around 15% of patients with PD are known to have a first-degree relative who is also affected by this disease [2]. Mutations in several specific genes have been conclusively shown to be associated with PD. These genes code for alpha-synuclein (SNCA), parkin (PRKN), leucine-rich repeat kinase 2 (LRRK2 or dardarin), PTEN-induced putative kinase 1 (PINK1), DJ-1 and ATP13A2 [3,4]. The most extensively studied PD-related genes are SNCA and LRRK2 [1]. Mutations in SNCA, LRRK2 and glucocerebrosidase (GBA) are associated with most of the PD related cases [1]. Nevertheless, very less amount of work has been done related to protein interactions specific to the disease state.

Network science is gradually altering our view of cell biology by offering unforeseen possibilities to understand the internal organization of a cell [5]. The developments of high-throughput data-collection techniques have brought insights to our understanding of diseases. Sincere amount of time and effort has to be devoted in order to analyse this vast amount of data if we want to
understand the interrelationships among disease-related genes and proteins [5]. In 2009, Taylor et al. [6] studied gene expression based weighted Protein-Protein Interaction (PPI) networks for breast cancer. They found that loss of gene co-expression of proteins interacting within the BRCA1-associated genome surveillance complex (BASC) is associated with poor outcomes of the disease. In 2011, Lee et al. [7] constructed protein-protein interaction (PPI) networks of abnormally expressed genes for schizophrenia, bipolar disease and major depression, and identified several disease markers like SBNO2 for schizophrenia, SEC24C for bipolar disorder, and SRRT for major depression. Recently, in April 2013, Ran et al. [8] constructed and analysed PPI networks for Essential Hypertension (EH), and suggested that blood pressure variation related to EH is orchestrated by an integrated PPI network with the protein encoded by NOS3 gene as its backbone.

In this study, PPI networks were constructed for PD using proteins which code for differentially expressed genes only in substantia nigra and frontal cerebral cortex. The PPI networks were constructed based on the following assumptions [7]

1. Expression level of most of the proteins and mRNAs in the brain are positively correlated.
2. Proteins with similar expression patterns are more likely to interact with each other.
3. Abundant proteins participate more in biological processes.

Topological analyses were performed to find out the significant network biomarkers. The association of these biomarkers with PD-related genes and neurotransmitters were studied. Several complexes were also studied in the networks. Changes of co-expression level of genes associated with the complexes from control to disease state were also studied. 37 unreported disease marker genes were identified of which eight were significantly involved in the core functional modules and four showed strong association with several neurotransmitters, including dopamine. Thus our study may provide insights into the potential targets for developing new treatments for PD.

Methods

Sources of microarray data

Figure 1 gives the flowchart of research methodology applied in this study. The raw data (CEL files) of microarray data series GSE8397 were downloaded from Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) and normalized by geRMA [9]. GSE8397 was published by Moran et al. in 2006 [10]. It contains 47 individual localized brain tissue samples of the substantia nigra (SN) (split into medial and lateral portions) and frontal cerebral cortex (FCC) associated with PD as well as control cases, using A (HG_U133A) and B (HG_U133B) Gene Chip per sample. 15 samples of medial parkinsonian SN (MSN), 9 samples of lateral parkinsonian SN (LSN) and 5 samples of parkinsonian FCC were taken. 8 MSN samples, 7 LSN samples and 3 FCC control samples were considered.

Our protein-interaction networks were built based on differentially expressed genes of MSN and LSN only. Initially we started a region wise study of three parts of the brain viz., MSN, LSN and FCC. When we performed 2-tailed t-test and SAM, we did not get any differentially expressed genes for FCC. MSN and LSN
separately yielded less number of differentially expressed genes. However, when we combined both MSN and LSN, it yielded significant number of differentially expressed genes. Therefore the data presented in our manuscript is the collection of genes present in combined MSN and LSN.

Selection of differentially expressed genes, annotation & gene ontology (GO) analysis

Both 2-tailed t-test [7] and SAM [11] were used separately to obtain all possible differentially expressed genes from the microarray data. Expression Analysis Systematic Explorer (EASE) [12] was used to convert the Affymetrix probe IDs into gene symbols. A particular module in Babelomics 4.3.0 [13], FatiGO (http://www.fatiigo.org/) [14], was used to extract relevant GO terms for a group of genes with respect to rest of the genes. FatiGO was used to find the over-representative biological processes, molecular functions, cellular components and KEGG pathways [15] involving the DE genes (p-value < 0.05) (Table 1). Among the GO terms, DE genes were most abundant in the over-representative biological processes. These DE genes were considered as the most significant genes in the dataset, and therefore subjected for network construction.

For the sake of clarity, we have denoted the set of significant DE genes extracted from GeneChip A using 2-tailed t-test, by the symbol $D_{A}^{2tt}$, the set of significant DE genes extracted from GeneChip A using SAM, by the symbol $D_{A}^{SAM}$, and the set of significant DE genes extracted from GeneChip B using 2-tailed t-test, by the symbol $D_{B}^{2tt}$. These sets of significant DE genes ($D_{A}^{2tt}$, $D_{A}^{SAM}$ & $D_{B}^{2tt}$) were subjected for construction of protein-protein interaction (PPI) networks.

Construction of the QQPPI networks

Two separate approaches were taken to construct the PPI networks. First, Genes2FANs (http://actin.pharm.mssm.edu/genes2FANs/) [16] was used to construct a Query-Query PPI (QQPPI) network, i.e., a network of protein-protein interactions consisting of query nodes only. Secondly, brain tissue specific and experimentally verified data was taken from POINeT (http://poinet.bioinformatics.tw/) [17] to create another QQPPI network. The two networks constructed by Genes2FANs and POINeT were separately viewed using the open source network visualization software Cytoscape 2.8.0 (http://www.cytoscape.org/) [18]. The two networks (developed by Genes2FANs and POINeT) were then merged to construct the final QQPPI network, which includes all the interactions present in both the individual networks. This final network was formatted and visualized using the graph editing software yEd (http://www.yworks.com/) [19]. The same procedure was repeated for the datasets $D_{A}^{2tt}$, $D_{A}^{SAM}$ and $D_{B}^{2tt}$. For the sake of clarity, we denote the merged QQPPI network formed by $D_{A}^{2tt}$ as $N_{A}^{2tt}$, the merged QQPPI network formed by $D_{A}^{SAM}$ as $N_{A}^{SAM}$, and the merged QQPPI network formed by $D_{B}^{2tt}$ as $N_{B}^{2tt}$ (Figure 2, 3, S1). Here this must be remembered that the algorithm for QQPPI network is built in such a way that a protein occurs only once in each of the networks.

Topological parameters of QQPPI networks

We analysed topological properties of these networks using the tYNA (http://tyna.gersteinlab.org/) [20] web interface. Global properties of the networks are given in Table 2. The topologically significant nodes were extracted from the networks in two steps:

1. In the networks, nodes with degree greater than or equal to the sum of mean and twice the standard deviation (S.D.), i.e.,
mean ±2S.D. of the degree distribution, were taken as hubs, i.e., High Connectivity (HC) nodes [21]. (Table 3)

(2) In the second step Betweenness centrality was taken as parameter to extract significant nodes. Betweenness centrality of the nodes in the QQPPI networks (Figure 2,3, S1) showed a varied distribution. Only a handful of nodes had betweenness score greater than 1000. However, almost 40–45% of nodes had zero betweenness. The node betweenness distribution was sorted in descending order and nodes with betweenness score lying in the top 50% of the distribution were selected. Among these sorted nodes, the nodes identified with degree less than the cut-off degree for HC nodes and directly connected to at least 2 HC nodes were selected as bottlenecks, i.e., High Betweenness but Low Connectivity (HBLC) nodes.

Identification of cliques

In this study, cliques with 3 nodes and 4 nodes (3-clique, 4-clique) were identified in \( N_{Int}^A \), \( N_{SAM}^A \) and \( N_{Int}^B \). The cliques were identified with the help of a self developed algorithm (File S1). To validate the authenticity and correctness of the algorithm, it was simulated for the network obtained from POINeT and the output of the program was compared with the list of cliques given in POINeT for that network, the results exactly matched. The development of the in house algorithm was necessary to find the cliques (three and more) in the merged networks (obtained from

Figure 2. QQPPI network built from the dataset obtained using t-tailed t-test (P<0.001) (GeneChip A). Orange coloured square nodes represent hubs (HC nodes). Yellow coloured triangular nodes represent bottlenecks (bottlenecks). The core functional module containing 3,4-cliques are represented using blue coloured edges. Non-hub non-bottleneck nodes are coloured green if they are directly connected to a hub or a bottleneck, and grey otherwise. Inset: Subset of the QQPPI network containing hubs and bottlenecks only.

doi:10.1371/journal.pone.0103047.g002
POINeT and Genes2FANs). Only 3-Cliques and 4-Cliques were obtained, and higher order cliques were absent in the network.

Identification of complexes containing clique forming proteins
A protein complex is a complex containing multiple proteins that interact with each other. They are in the form of quaternary structure, and the proteins in the complex are linked by non-covalent protein-protein interactions. The complexes in the PPI networks were identified with the help of the database CORUM [22]. The clique forming proteins were given as query in the CORUM database to find out the complexes containing this proteins. Furthermore, with the help of an in house algorithm (File S2) all the proteins associated with a specific complex were identified. A cut-off for the number of query proteins in a complex is assigned. For $N^2_{3ttt}$, complexes containing 5 or more query proteins were listed. Similarly for $N^2_{4SAM}$, complexes containing 4 or more query proteins were listed. In $N^2_{2ttt}$, since only 2 proteins are involved in a particular complex, we did not consider this QQPPI network for complex detection. The programs to find

Table 2. Global properties of the networks.

| Network source | Number of nodes | Number of edges | Average degree | Highest degree | Average betweenness | Highest betweenness |
|----------------|-----------------|-----------------|----------------|----------------|--------------------|--------------------|
| $N^4_{3ttt}$    | 406             | 690             | 3.4            | 47             | 583.42             | 21,286.48          |
| $N^4_{4SAM}$    | 121             | 172             | 2.8            | 21             | 115.23             | 1888.753876        |
| $N^4_{2ttt}$    | 73              | 85              | 2.33           | 11             | 81.62              | 855.18             |

doi:10.1371/journal.pone.0103047.t002
Comparison with the study of Moran et al. [10]

Different analytic approaches can be taken to analyse the same microarray data with different set of goals [7]. The original contributors of the microarray data series GSE8397 were Moran et al., who focused on establishing the transcriptomic expression profile of the medial & lateral substantia nigra and the superior frontal cortex. The differentially regulated genes identified in their study were compared to the results of our study.

Results & Discussion

Study of Differential Expression (DE) of genes

Involvement of substantia nigra (SN) in PD is well known [23, 24, 25]. PD related motor symptoms mainly occur due to the depletion of up to 60% of dopaminergic neurons and aggregation of round, hyaline neuronal cytoplasmic inclusions called Lewy Bodies (LBs) in SN [24, 25]. Significant involvement of frontal cortex in PD has also been reported [10, 25, 26]. The dataset (GSE8397) provided by Moran et al. [10] is the only available dataset till date which covers the tissue samples both from substantia nigra and frontal cerebral cortex. Therefore we have considered these datasets for our study.

Initially the microarrays in GSE8397 were analyzed using 2-tailed t-test. Each disease sample group was paired with the control group. SAM test statistic. Probes corresponding to a portion of the genes (P value) of observing a value as extreme or more extreme of the distribution. Gene level co-expression analysis of interacting proteins

Pearson correlation coefficient was used to find out the gene level co-expression of interacting proteins in the QQPPI networks. In the QQPPI networks, gene level co-expression of each pair of interacting proteins was used to assign weight to the edges of the network. Percentage change in co-expression of interacting proteins was also calculated.

Table 3. Cut-off determination for hubs (HC nodes).

| GeneChip A (HG_133A) |  |  |  |
|---------------------|----------------|----------------|----------------|
|                      | Mean (M) | Standard Deviation (S) | Cut-off (M×2*S) |
| $N^A_{2HM}$         | 3.4      | 4.2              | 11.8=12        |
| $N^A_{SAM}$         | 2.8      | 2.9              | 8.6=9          |
| GeneChip B (HG_133B) |  |  |  |
|                      | 2.33     | 2.29             | 6.9=7          |

doi:10.1371/journal.pone.0103047.t003

Table 4. Number of obtained hubs (HC nodes) & bottlenecks (HBLC nodes).

| GeneChip A (HG_133A) | Number of hubs (HC nodes) | Number of bottlenecks (HBLC nodes) |
|----------------------|----------------------------|------------------------------------|
|                      | $N^A_{2HM}$ | $N^A_{SAM}$ | $N^B_{2HM}$ | $N^B_{SAM}$ |
|                      | 19           | 41           | 5           | 14           |
| GeneChip B (HG_133B) | 5            | 7            |             |             |

doi:10.1371/journal.pone.0103047.t004

Table 5. Hubs & bottlenecks in $N^A_{2HM}$.

| Hubs     | YWHAZ, ACTB, ACTG1, YWHA8, YWHAE, MAPK1, MAP3K14, DISC1, APP, VCL, VIM, FTSJ1, HSFA1A, IKBK8, YWHAQ, ARR8B2, EEF1A1, SNCA, SGSTM1 |
|----------|-----------------------------------------------------------------------------------------------------------------------------------|
| Bottlenecks | HDAC4, TGFB1, STUB1, ANXA2, KPNB1, TERT, STX1A, SPTBN1, AKIN1, IQGAP1, RAD21A, PS3, CHUK, MCL1, DAPK1, PAR3, TIP2, ACTN2, TAF9, IGFR1, CDC25B, IARS, CTNNA1, PTPN3, IRAKI1, TFRC, VASP, MAP3K7IP2, ADAM17, CYCS, MAP2K4, WEE1, SF3B1, DSN1, SRRM2, BAG2, C10BP, PHB, YWHAH, GSN, MARCKS |

doi:10.1371/journal.pone.0103047.t005

In SAM, Fold changes are also specified to guarantee that significant genes change at least at a pre-specified amount. This means that the absolute value of the average expression levels of a gene under each of two conditions must be greater than the fold change to be called positive and less than the inverse of the fold change to be called negative. This way, SAM gives better result in sample group in the t-tests. 2-tailed t-test is a measure of the statistical significance of the dataset, in terms of a test statistic t, which is given by:

$$t = \frac{x - \bar{y}}{\sqrt{s_x^2/n + s_y^2/m}}$$

where $x$ and $y$ are the sample means, $S_x$ and $S_y$ are the sample standard deviations, $n$ and $m$ are the sample sizes for two samples, $x$ and $y$. Under the null hypothesis, this test returns the probability (P value) of observing a value as extreme or more extreme of the test statistic. Probes corresponding to a portion of the genes showed significant changes in signal intensities in disease sample groups, as compared to the control. These genes were selected as Differentially Expressed (DE) genes.

Previously, 2-tailed t-test has been successfully used to select differentially expressed data from microarray datasets [7]. However, 2-tailed t-test does not give any up-regulated or down-regulated gene information. Therefore, Significance Analysis of Microarrays (SAM) was used to identify up-regulated (UR) or down-regulated (DR) DE genes in the disease state. SAM calculates a test statistic for relative difference in gene expression based on permutation analysis of expression data, and False Discovery Rate [27] which is given by:

$$FDR = \frac{\text{Median}(90th \text{ percentile}) \text{ of } \# \text{ of falsely called genes}}{\text{Number of significant genes}}$$

In SAM, Fold changes are also specified to guarantee that significant genes change at least at a pre-specified amount. This means that the absolute value of the average expression levels of a gene under each of two conditions must be greater than the fold change to be called positive and less than the inverse of the fold change to be called negative. This way, SAM gives better result in...
terms of differential expression than 2-tailed $t$-test as the latter does not take into account fold changes to determine significance of average gene expression levels.

1443 and 1518 DE genes were reported using 2-tailed $t$-test ($P$ values<0.001) and SAM (FDR 0.19%) respectively from GeneChip A (HG_U133A). Out of the 1518 SAM reported DE genes, 293 genes were up-regulated (UR) and 1225 were down-regulated (DR).

Similar methodology (2-tailed $t$-test at $P$ values<0.001 and SAM at FDR 0.19%) was followed to analyse GeneChip B (HG_U133B), but no significant DE gene was found. However when we increased the $P$ value ($P<0.05$) of 2-tailed $t$-test, 1606 genes were found to be DE.

These DE genes were selected for subsequent ontological analyses followed by network analyses as their abnormal gene expression profiles in disease state indicated probable involvement in disease pathology.

### Functional analysis of DE genes

The DE genes were subjected to FatiGO [14] for functional analysis. The over-representative GO terms ($P$ value<0.05) were considered. Among these GO terms, the over-representative biological processes showed large number of DE genes as compared to other GO terms and KEGG pathways (Table 1). Therefore, the DE genes involved in the biological processes were selected in our study for subsequent network generation based on a similar approach presented in a previous study [28]. For the dataset obtained from GeneChip A (HG_U133A) using 2-tailed $t$-test ($P<0.001$), 779 genes (distributed among 792 biological processes) were chosen as significant DE genes ($D_{SAM}^A$). Similarly, for the dataset obtained from GeneChip A (HG_U133A) using SAM, 207 genes (distributed among 381 biological processes) were chosen as significant DE genes ($D_{SAM}^B$). For the dataset obtained from GeneChip B (HG_U133B) using 2-tailed $t$-test ($P<0.05$), 221

| Table 6. Hubs & bottlenecks in $N_{SAM}^A$. |
|----------------------------------------------|
| **Hubs** | YWHAZ, YWHAB, CSNK2A1, CLTC, CDC42 |
| **Bottlenecks** | PRKCZ, APC, SNCA, NFKBIA, IQGAP1, TSC2, IGF1R, HSPA1A, OCR1, PARD3, CLTB, TH, ATP5A1, TUBB |

| Table 7. Hubs & bottlenecks in $N_{SAM}^B$. |
|----------------------------------------------|
| **Hubs** | MAPK1, YWHA, MAPK8, ACTB, PAK1 |
| **Bottlenecks** | CDC42, MAP3K2, MAP1B, MBP, NDE1, DUSP1, AKT2 |

Figure 4. Graphical structure of a simple PPI network. High Connectivity (HC) nodes or hubs: A & C. High Betweenness but Low Connectivity (HBLC) nodes or bottlenecks: B. doi:10.1371/journal.pone.0103047.g004
genes (distributed among 61 biological processes) were chosen as the significant DE genes ($D^{DE}_{PD}$).

Topological analyses of QQPPI networks

A PPI network is commonly represented as an undirected (edges have no direction) graph, $G = (V, E)$, where $V$ is the set of nodes (proteins) and $E = \{(u, v) | u, v \in V\}$ is the set of edges (protein interactions). Thus the networks we studied are undirected and unweighted protein-protein interaction networks based on DE genes of PD microarray data.

QQPPI networks can be characterized by several topological parameters. Out of these, one of the most basic yet essential parameter is node degree, or connectivity. It signifies the number of edges incident on particular node. For a node $v \in V$, the set of edges incident on $v$ is denoted as $N_v$, where $N_v = \{(u, v) | u, v \in E\}$. The cardinality of $N_v$, i.e., $|N_v|$ is $v$’s connectivity, or degree in $G$, also known as deg($v$). High connectivity (HC) of a node indicates that the node (protein) has direct interaction (physical interaction and/or complex formation) with many other distinct nodes (proteins). Proteins with high connectivity are considered to be essential hubs of the network, whose removal would result in an overall collapse of the global structure of the network [6]. We have extracted hubs from the QQPPI networks using the criterion described in section 2.4. Table 4 gives the number of hubs obtained from the QQPPI networks. Hub genes identified in the QQPPI networks are listed in Table 5, 6 and 7. Betweenness centrality of a node $v$ is given by the expression:

$$g(v) = \sum_{s \neq v \neq t} \frac{\sigma_{st}(v)}{\sigma_{st}} \tag{3}$$

where $\sigma_{st}$ is the total number of shortest paths from node $s$ to node $t$, and $\sigma_{st}(v)$ is the total number of shortest paths that pass through $v$. Betweenness centrality quantifies the flow of information

### Table 8. Numbers of 3 and 4-cliques in the QQPPI networks.

| GeneChip A (HG_133A) | 3-cliques | 4-cliques |
|-----------------------|-----------|-----------|
| $N^{3}_{2AM}$         | 126       | 12        |
| $N^{4}_{2AM}$         | 29        | 2         |

| GeneChip B (HG_133B) | 3-cliques | 4-cliques |
|-----------------------|-----------|-----------|
| $N^{3}_{2AM}$         | 7         | 0         |

doi:10.1371/journal.pone.0103047.t008

### Table 9. List of complexes for the network $N^{4}_{2AM}$ and $N^{4}_{2AM'}$.

| Gene names | Complex* |
|------------|----------|
|            |          |
| CD2BP2, DDX17, NF2, PRPF8, SF3A2, SF3B1, SRRM2, WBP11 | Spliceosome (ID: 351) |
| ACTB, ACTG1, NF2, SMARCA4, SMARC1, SMARC2 | Polymtomo and BAF containing complex(ID: 149, 189) |
| MAP2K1, MAPK1, YHWHB, YWHAE, YWHAH, YWHAZ | Ksr1 complex (ID: 5909, 5937) |
| ACTB, NF2, SMARCA4, SMARC1, SMARC2 | Nucleosomal methylation activator complex (ID: 86), BAF complex(ID: 566), LARC complex (ID: 778) |
| ACTB, NF2, SMARC1, SMARC2, VDR | Emerin complex 320(ID: 5614) |
| APC, APP, PSMC4, PSMD1, PSMD4 | Proteasome (ID: 181, 193) |
| EEF1A1, MYB, RPLP0, RPLP1, RPS3 | Nop56p-associated pre-rRNA complex(ID: 3055) |
| MAP2K1, YHWHB, YWHAE, YWHAH, YWHAZ | Ksr1 complex(ID: 5886, 5936) |
| NF2, SMARCA4, SMARC1, SMARC2, VDR | WINAC complex(ID: 1230) |
| PNN, PRPF8, SF3A2, SF3B1, SRRM2 | C complex spliceosome (ID: 1181) |
| $N^{4}_{2AM}$ |          |
| AMPH, AP2A2, AP2M1, EPS15, TH | Epsin-clathrin complex (ID: 1228) |
| AMPH, CLTC, DN1M, EPS15, SYNU1 | Endocytic coat complex (ID: 5344) |
| AMPH, CLTC, DN1M, SYNU1, TH | Endocytic coat complex (ID: 5345) |
| APC, PSMG1, PSMG2, PSMG7, TH | Proteasome complex(ID: 181, 191, 192, 193, 194) |
| APC, CDC42, IQGAP1, TH | APC-IQGAP1-Rac1 complex (ID: 3011), APC-IQGAP1-Cdc42 complex (ID: 3012) |
| CDC42, PARD3, PRK2C2, TH | CDC42-Par6c-Par3-Prkcz complex (ID: 804) Tiam1-Par-3-APKzeta complex (ID: 1023) |
| CSNK2A1, TH, YHWHB, YWHAZ | Ksr1-C2-MEK-14-3-3 complex, PDGF treated (ID: 5936) |

* The complexes are given along with their CORUM IDs.

doi:10.1371/journal.pone.0103047.t009
through a node in the network. In case of a PPI network, it specifies how a node influences the communication among other nodes. Therefore, in a QQPPI network, betweenness centrality helps to locate important but not very highly connected nodes. Nodes are also considered as bottlenecks [35]. Yu et al. [34] described that in case of biological networks, the Highly betweened but lowly connected (HBLC) nodes, and their importance in the context of biological networks. Gonî et al. [33] studied the properties of High Betweenness but Low Connectivity (HBLC) nodes, and their importance in the context of biological networks. The Highly betweened but lowly connected ones, as the critical role of highly connected nodes (hubs) in the network modules prevent them from substantial fluctuation. Recently, it was shown that betweenness centrality can also be an important parameter for finding lowly connected (non-hub) but important nodes [34,35]. Proteins with low connectivity but high betweenness may play a key role in the modular structure in the yeast interactome. Gursoy et al. [36] studied the properties of High Betweenness but Low Connectivity (HBLC) nodes, and their importance in the context of biological networks. The Highly betweened but lowly connected nodes are also considered as bottlenecks [35]. Yu et al. [35] Suggested that HBLC nodes are more essential, and betweenness centrality is found to be a more significant indicator of essentiality than degree. Table 4 gives the number of bottlenecks obtained from the QQPPI networks. Table 5, 6 and 7 gives the bottlenecks of our QQPPI networks. Figure 4 represents the graphical structure of a simple PPI network containing hubs and bottlenecks. Table S1, S2 and S3 lists all the nodes, hubs and bottlenecks in $N_{2int}^A$, $N_{SAM}^A$ and $N_{2int}^B$, along with their topological parameters as obtained from TYNNA.

### Identification of cliques & complexes

A clique $Q \subseteq V$ is a subset of the vertices of $G$ (refer to section 5.3) such that $\forall i,j \in Q : \{i,j\} \in E$. In a PPI network, a clique signifies that every pair of proteins physically interacts with each other. Cliques have been used to identify functional units [37] and physical complexes [38] in PPI networks. Several three and four cliques were identified in the QQPPI networks using a self-developed algorithm (refer to section 2.5). Most of these cliques are overlapping. Table 8 shows the number of cliques identified in the QQPPI networks ($N_{2int}^A$, $N_{SAM}^A$ and $N_{2int}^B$). Table 9 shows the complexes formed by individual and overlapping cliques in $N_{2int}^A$ and $N_{SAM}^A$.

For each QQPPI network ($N_{2int}^A$, $N_{SAM}^A$ and $N_{2int}^B$), 3-cliques and 4-cliques were combined to detect tightly knitted sub-networks, which are the core functional modules in the QQPPI networks [7] (Figure 2, 3, S1). Table S4 lists the nodes in the functional modules, along with their connectivity, betweenness, and their numbers of occurrences in 3- and 4-cliques. For each QQPPI network, it can be observed that most of the hubs and bottlenecks belonged to the core functional modules. Several cliques in the sub-networks belonging to $N_{2int}^A$ and $N_{SAM}^A$ were found to be involved in already known protein complexes (Table 9).

### Table 10. Co-expression analysis of proteins interacting within a complex ($N_{2int}^A$).

| Node 1 | Node 2 | Control (C) | Disease (D) | Change (C–D) | Complex |
|--------|--------|-------------|-------------|--------------|---------|
| CD2BP2 | PRPF8  | 0.182452    | 0.377959    | −0.195506    | Spliceosome (ID: 351) |
| CD2BP2 | SF3A2  | −0.49456    | 0.300699    | −0.795258    |         |
| CD2BP2 | WBP11  | 0.064197    | −0.18898    | 0.253176     |         |
| PRPF8  | SF3A2  | −0.09299    | −0.01542    | −0.07757     |         |
| SF3A2  | SF3B1  | 0.236131    | −0.15777    | 0.393901     |         |
| SF3A2  | SRRM2  | 0.210102    | 0.531593    | −0.321490    |         |
| SF3A2  | WBP11  | −0.10021    | −0.16228    | 0.062070     |         |
| ACTB   | ACTG1  | 0.344993    | 0.571264    | −0.226271    | Polybromo and BAF containing complex (ID: 149, 189) |
| ACTB   | SMARCA4| 0.272319    | 0.085326    | 0.186992     |         |
| ACTG1  | NF2    | −0.2271     | 0.0839      | −0.311       |         |
| SMARCA4| SMARCC1| −0.32228    | −0.2122     | −0.110080    |         |
| SMARCC1| SMARCC2| 0.197918    | 0.250794    | −0.052876    |         |
| MAP2K1 | MAPK1  | 0.705468    | 0.59637     | 0.109098     | Ksr1 complex (ID: 5909, 5937) |
| YWHAE  | YWHAH  | −0.30185    | −0.16978    | −0.132070    |         |
| YWHAE  | YWHAZ  | −0.24657    | −0.06473    | −0.18184     |         |
| PSMC4  | PSMD1  | 0.305936    | 0.155939    | 0.149996     | Proteasome (ID: 181, 193) |
| PSMC4  | PSMD4  | 0.030223    | 0.49093     | −0.460706    |         |
| PSMD1  | PSMD4  | 0.129277    | 0.429546    | −0.300269    |         |
| EEF1A  | RPL1   | −0.62308    | −0.37849    | −0.244589    | Nop56p-associated pre-rRNA complex (ID: 3055) |
| PRPF8  | SF3A2  | −0.09299    | −0.01542    | −0.07757     | C complex spliceosome (ID: 1181) |
| SF3A2  | SF3B1  | 0.236131    | −0.15777    | 0.393901     |         |
| SF3A2  | SRRM2  | 0.210102    | 0.531593    | −0.321490    |         |

doi:10.1371/journal.pone.0103047.t010
Gene level co-expression analysis of proteins interacting within a complex

The Pearson correlation coefficient ($r$) is a measure of the linear dependence between two variables giving a value between +1 and −1 inclusive. It is used as a measure of the strength of linear dependence between two variables. It is defined as the covariance of the two variables divided by the product of their standard deviations.

Table 10 and Table 11 lists the values of Pearson correlation coefficient ($r$) of two interacting complex forming nodes and their change in both control and disease states (in $N_{2\text{ttt}}^d$ and $N_{\text{SAM}}^d$ respectively). Table S5, S6 and S7 shows the Pearson correlation coefficient ($r$) of proteins interacting within cliques, along with net difference of $r$ between control and disease samples and their percentage of maximum possible change, in the core functional modules detected in $N_{2\text{ttt}}^d$, $N_{\text{SAM}}^d$ and $N_{\text{SAM}}^b$ respectively.

Spliceosome complex (ID: 351) has been found to be the most significant in terms of change in co-expression in $N_{2\text{ttt}}^d$ (Table 10). Moreover, Ksr1-CK2-MEK-14-3-3 complex, PDGF treated (ID: 5936) shows significant difference in co-expression value in $N_{\text{SAM}}^d$ (Table 11).

### Association of disease markers with cliques and neurotransmitters

Having identified the topologically significant (HC and HBLC) nodes, we then set out to study their association with PD. We used Genotator meta-database [39] and the text mining engine PubMed (http://www.ncbi.nlm.nih.gov/pubmed) for this purpose. 13 hubs and 15 bottlenecks in $N_{2\text{ttt}}^d$ and 3 hubs and 9

---

**Table 11. Co-expression analysis of proteins interacting within a complex ($N_{\text{SAM}}^d$).**

| Node 1 | Node 2 | Control (C) | Disease (D) | Change (C–D) | Complex |
|--------|--------|-------------|-------------|--------------|---------|
| AMPH  | AP2A2  | 0.895323    | 0.711618    | 0.183705     | Epsin-clathrin complex (ID: 1228) |
| AP2A2 | AP2M1  | 0.896811    | 0.71299     | 0.183821     |         |
| AP2A2 | EPS15  | 0.680562    | 0.130673    | 0.549888     |         |
| AMPH  | CLTC   | 0.835258    | 0.766836    | 0.068421     | Endocytic coat complex (ID: 5344) |
| CLTC  | EPS15  | 0.594193    | 0.346006    | 0.248186     |         |
| CLTC  | SYNJ1  | 0.645271    | 0.769517    | −0.124245    |         |
| DNM1  | EPS15  | 0.752444    | 0.283483    | 0.468961     |         |
| EPS15 | SYNJ1  | 0.694805    | 0.449957    | 0.244848     |         |
| PSMA1 | PSMB2  | 0.389236    | 0.512285    | −0.123048    | Proteasome complex(ID: 181, 191, 192, 193, 194) |
| PSMA1 | PSMB7  | 0.515788    | 0.620496    | −0.104708    |         |
| PSMB2 | PSMB7  | 0.102045    | 0.310781    | −0.208735    |         |
| APC   | IQGAP1 | −0.61332    | −0.33299    | −0.280329    | APC-IQGAP1-Rac1 complex (ID: 3011), APC-IQGAP1-Cdc42 complex (ID: 3012) |
| CDC42 | IQGAP1 | −0.18484    | −0.2834     | 0.098559     |         |
| CDC42 | PARD3  | −0.13129    | −0.35908    | 0.222790     | CDC42-Par6c-Par3-Prkcz complex (ID: 804), Tiam1-Par-3-apKIC-zeta complex (ID: 1023) |
| CDC42 | PRKCRZ | 0.762057    | 0.706097    | 0.055960     |         |
| PARD3 | PRKCRZ | −0.13645    | −0.44763    | 0.311180     |         |
| CSNK2A1| YWHA8  | 0.253246    | 0.672328    | −0.419082    | Ksr1-CK2-MEK-14-3-3 complex, PDGF treated (ID: 5936) |
| TH    | YWHA8  | −0.47327    | 0.157579    | −0.630848    |         |
| TH    | YWHAZ  | −0.36101    | −0.1174     | −0.243609    |         |

**Table 12. Previously reported PD-associated disease markers in $N_{2\text{ttt}}^d$ and $N_{\text{SAM}}^d$.**

| $N_{2\text{ttt}}^d$ Hubs | YWHAZ, YWHA8, YWHA8E, MAPK1, DISC1, APP, VCL, VIM, HSPA1A, IKBKB, YWHAQ, SNCA, SQSTM1 |
| $N_{\text{SAM}}^d$ Hubs | HDAC4, TGFBI1, SET, SPTBN1, RAD23A, RPS3, CHUK, DAPK1, IGF1R, IRAK1, CYCS, MAP2K4, SRRM2, PHB, YWHAH |

**Table 13. Previously reported PD-associated disease markers in $N_{2\text{ttt}}^d$ and $N_{\text{SAM}}^d$.**

| $N_{2\text{ttt}}^d$ Bottlenecks | HDAC4, TGFBI1, SET, SPTBN1, RAD23A, RPS3, CHUK, DAPK1, IGF1R, IRAK1, CYCS, MAP2K4, SRRM2, PHB, YWHAH |
| $N_{\text{SAM}}^d$ Bottlenecks | HDAC4, TGFBI1, SET, SPTBN1, RAD23A, RPS3, CHUK, DAPK1, IGF1R, IRAK1, CYCS, MAP2K4, SRRM2, PHB, YWHAH |
### Table 13. Previously unreported disease markers in $N_{2HI}^d$.

| Hubs      | Degree | Number of occurrence in 3-cliques | Number of occurrence in 4-cliques |
|-----------|--------|-----------------------------------|-----------------------------------|
| *ACTB     | 29     | 17                                | 6                                 |
| *ACTG1    | 23     | 22                                | 5                                 |
| MAP3K14   | 18     | 14                                | 5                                 |
| FTSJ1     | 13     | 1                                 | 0                                 |
| *ARRB2    | 12     | 8                                 | 2                                 |
| EEF1A1    | 12     | 5                                 | 1                                 |
| **STUB1** | 2669.6 | 4                                 | 1                                 |
| ANXA2     | 2425.6 | 4                                 | 1                                 |
| KPNB1     | 2313.0 | 4                                 | 0                                 |
| **STX1A** | 1758.5 | 1                                 | 0                                 |
| AXIN1     | 1649.0 | 0                                 | 0                                 |
| IQGAP1    | 1591.5 | 5                                 | 0                                 |
| MCL1      | 1149.0 | 0                                 | 0                                 |
| PARD3     | 1031.7 | 0                                 | 0                                 |
| TJP2      | 995.5  | 4                                 | 1                                 |
| ACTN2     | 989.1  | 2                                 | 0                                 |
| TAF9      | 973.4  | 0                                 | 0                                 |
| CDC25B    | 876.2  | 3                                 | 0                                 |
| IARS      | 773.3  | 1                                 | 0                                 |
| **CTNNA1**| 695.8  | 8                                 | 2                                 |
| PTPN3     | 666.6  | 0                                 | 0                                 |
| **TFRC**  | 522.4  | 1                                 | 0                                 |
| VASP      | 500.2  | 3                                 | 1                                 |
| MAP3K7IP2 | 484.3  | 1                                 | 0                                 |
| ADAM17    | 464.6  | 0                                 | 0                                 |
| WEE1      | 392.7  | 0                                 | 0                                 |
| SF3B1     | 375.7  | 2                                 | 0                                 |
| DSN1      | 342.8  | 1                                 | 0                                 |
| BAG2      | 253.0  | 4                                 | 1                                 |
| C1QB8     | 236.1  | 2                                 | 0                                 |
| **GSN**   | 110.1  | 6                                 | 2                                 |
| **MARCKS**| 98.7   | 0                                 | 0                                 |

*Topologically significant disease markers.

### Table 14. Previously unreported disease markers in $N_{SAM}^d$.

| Hubs      | Degree | Number of occurrence in 3-cliques | Number of occurrence in 4-cliques |
|-----------|--------|-----------------------------------|-----------------------------------|
| *CSNK2A1  | 12     | 3                                 | 0                                 |
| *CLTC     | 11     | 7                                 | 1                                 |
| **IQGAP1**| 284.1  | 2                                 | 0                                 |
| OCRL      | 97.3   | 0                                 | 0                                 |
| **PARD3** | 79.4   | 3                                 | 0                                 |
| CLTB      | 77.6   | 0                                 | 0                                 |
| TUBB      | 23.3   | 0                                 | 0                                 |

*Topologically significant disease markers.

doi:10.1371/journal.pone.0103047.t013

doi:10.1371/journal.pone.0103047.t014
### Table 15. Brief description of previously unreported disease markers in $N_{2tar}^d$.

| Hubs (Official symbol) | Full name | Brief description |
|------------------------|-----------|-------------------|
| *ACTB                  | actin, beta | This gene encodes one of six different highly conserved actin proteins, which are involved in cell motility, structure, and integrity. |
| *ACTG1                 | actin, gamma 1 | Actins are highly conserved proteins that are involved in various types of cell motility, and maintenance of the cytoskeleton. |
| MAP3K14                | mitogen-activated protein kinase kinase 14 | It is a serine/threonine protein-kinase which binds to TRAF2 and stimulates NF-kappaB activity. |
| FTSJ1                  | FtsJ RNA methyltransferase homolog 1 (E. coli) | It encodes a member of the methyltransferase superfamily which localizes to the nucleolus, binds to S-adenosylmethionine, and may be involved in the processing and modification of ribosomal RNA. |
| γARRB2                 | arrestin, beta 2 | This protein exhibits sensitized dopamine release in mice. |
| EEF1A1                 | eukaryotic translation elongation factor 1 alpha 1 | This gene encodes an isoform of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. |

| Bottlenecks (Official symbol) | | |
|-------------------------------| | |
| STUB1                         | STIP1 homology and U-box containing protein 1, E3 ubiquitin protein ligase | It is a ubiquitin ligase/cochaperone that participates in protein quality control by targeting a broad range of chaperone protein substrates for degradation. |
| ANXA2                         | annexin A2 | This gene encodes a member of the calcium-dependent phospholipid-binding protein family and plays a role in the regulation of cellular growth and in signal transduction pathways. |
| KPNB1                         | karyopherin (importin) beta 1 | The protein encoded by this gene is a member of the importin beta family which interacts with the FG repeats of nucleoporins for translocation through the pore complex. |
| γSTX1A                        | syntaxin 1A (brain) | Syntaxin 1A regulates dopamine transporter activity, phosphorylation and surface expression. |
| AXIN1                         | axin 1 | This gene encodes a cytoplasmic protein which contains a regulation of G-protein signaling (RGS) domain and a dishevelled and axin (DIX) domain. |
| MCL1                          | myeloid cell leukemia sequence 1 (BCL2-related) | This gene encodes an anti-apoptotic protein, which is a member of the Bcl-2 family. |
| TJLP2                         | tight junction protein 2 | This gene encodes a zonula occluden that is a member of the membrane-associated guanylate kinase homolog family which functions as a component of the tight junction barrier in epithelial and endothelial cells. |
| ACTN2                         | actinin, alpha 2 | Alpha actinins belong to the spectrin gene superfamily which represents a diverse group of cytoskeletal proteins, including the alpha and beta spectrins and dystrophins. |
| TAF9                          | TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 32 kDa | Protein encoded by this gene participates in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. |
| CDC25B                       | cell division cycle 25B | CDC25B is a member of the CDC25 family of phosphatases which activates the cyclin dependent kinase CDC2 by removing two phosphate groups and it is required for entry into mitosis. |
| IARS                         | isoleucyl-tRNA synthetase | It catalyzes the aminoacylation of tRNA by their cognate amino acid. It is thought to be among the first proteins that appeared in evolution. |
| γCTNNA1                      | catenin (cadherin-associated protein), alpha 1, 102 kDa | Protein encoded by this gene associates with the cytoplasmic domain of a variety of cadherins. |
| PTPN3                        | protein tyrosine phosphatase, non-receptor type 3 | The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family which are signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. |
| γTFRC                        | transferrin receptor | It is necessary for development of erythrocytes and the nervous system. |
| VASP                         | vasodilator-stimulated phosphoprotein | It is a member of the Ena-VASP protein family. It contains an EHV1 N-terminal domain that binds proteins containing E/D/FPXXXD/E motifs and targets Ena-VASP proteins to focal adhesions. |
| MAP3K7IP2                    | MAP3K7 binding protein 2 | The protein encoded by this gene is an activator of MAP3K7/TAK1, which is required for the IL-1 induced activation of nuclear factor kappaB and MAPK8/ JNK. |
| ADAM17                       | ADAM metallopeptidase domain 17 | This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family which has been implicated in a variety of biologic processes like fertilization, muscle development, and neurogenesis. |
| WEE1                         | WEE1 homolog (S. pombe) | This gene encodes a nuclear protein, which is a tyrosine kinase belonging to the Ser/Thr family of protein kinases. |
| SF3B1                        | splicing factor 3b, subunit 1, 155 kDa | This gene encodes subunit 1 of the splicing factor 3b protein complex. |
Table 15. Cont.

| Hubs (Official symbol) | Full name | Brief description |
|------------------------|-----------|------------------|
| DSTN | dextrin (actin depolymerizing factor) | The product of this gene belongs to the actin-binding proteins ADF family which is responsible for enhancing the turnover rate of actin in vivo. |
| BAG2 | BCL2-associated athanogene 2 | BAG proteins compete with Hip for binding to the Hsc70/Hsp70 ATPase domain and promote substrate release. |
| C1QBP | complement component 1, q subcomponent binding protein | It associates with C1r and C1s in order to yield the first component of the serum complement system and is known to bind to the globular heads of C1q molecules and inhibit C1 activation. |
| *GSN | Gelsolin | The protein encoded by this gene binds to the “plus” ends of actin monomers and filaments to prevent monomer exchange. |
| †MARCKS | myristoylated alanine-rich protein kinase C substrate | The protein encoded by this gene is a substrate for protein kinase C. It is localized to the plasma membrane and is an actin filament crosslinking protein. |

*Topologically significant disease markers.
†disease markers associated with dopamine.
doi:10.1371/journal.pone.0103047.t015

bottlenecks in $N^{d}_{SAM}$ were found to be associated with PD (Table 12). However, 6 hubs, 26 bottlenecks in $N^{d}_{2m}$ and 2 hubs, 5 bottlenecks in $N^{d}_{SAM}$ were unreported for PD (Table 13, 14). Due to the lack of topologically significant nodes in $N^{b}_{2m}$, we did not consider $N^{b}_{2m}$ for further analysis. Thus 39 (6+26+2+5 = 39) nodes were obtained from our QQPPI networks which were not previously known to be associated with PD. Among these 39 nodes, 2 nodes (IQGAP1 and PARD3) were common for both $N^{d}_{2m}$ and $N^{d}_{SAM}$. Therefore, these 39 (39−2 = 37) topologically significant nodes (hubs & bottlenecks) were considered as disease biomarkers in our study. The list of these genes, along with their symbols, names and brief description of their functions are shown in Tables 15 and 16.

These 37 unique disease markers ($N^{d}_{2m}$ and $N^{d}_{SAM}$) were then subjected to detailed analysis about their association in cliques and neurotransmitters. Interestingly it was found that 8 (CSNK2A1, CLTC, PARD3, IQGAP1, ACTB, ACTG1, CTNNA1 and GSN) out of the 37 nodes were strongly associated with cliques that form the core functional modules of the networks. Furthermore, significant changes in co-expression levels were observed between control and disease states in most of these core forming nodes (Table 17).

PD is characterised by the loss of dopaminergic neurons in the substantia nigra pars compacta [40]. Association of PD and loss of dopamine neurotransmitter has been established [24]. Other than dopamine, several neurotransmitters viz., choline, serotonin, noradrenaline, glutamate and GABA are also involved with PD-specific motor and non-motor symptoms [23]. We studied the association of the 37 unreported genes with any of these neurotransmitters. Four (ARRB2, STX1A, TFR2 and MARCKS) out of the 37 markers were found to be associated with several neurotransmitters including dopamine (Table 18) [40–52].

These 37 unreported proteins may be considered as important disease marker genes. However, the 8 clique-forming proteins and the 4 neurotransmitter (including dopamine) associated proteins

Table 16. Brief description of previously unreported disease markers in $N^{d}_{SAM}$.

| Hubs (Official symbol) | Full name | Brief description |
|------------------------|-----------|------------------|
| *CSNK2A1 | casein kinase 2, alpha 1 polypeptide | It phosphorylates acidic proteins such as casein. |
| *CLTC | clathrin, heavy chain | It is a major protein component of the cytoplasmic face of coated vesicles and coated pits, which is involved in the intracellular trafficking of receptors and endocytosis of a variety of macromolecules. |
| OCLRC | oculocerebrorenal syndrome of Lowe | This gene encodes a phosphatase enzyme that is involved in actin polymerization and is found in the trans-Golgi network. |
| *PARD3 | par-3 family cell polarity regulator | This gene encodes a member of the PARD protein family which affects asymmetrical cell division and direct polarized cell growth. |
| CLTB | clathrin, light chain B | Clathrin is a large, soluble protein composed of heavy and light chains which functions as the main structural component of the lattice-type cytoplasmic face of coated pits and vesicles. |
| TUBB | tubulin, beta class I | It is the major constituent of microtubules which binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. |

*Topologically significant disease markers.
doi:10.1371/journal.pone.0103047.t016
showed significant topological and functional importance in the QQPPI networks. Therefore, these 12 (8 + 4) proteins may be considered as key disease markers or biomarkers for PD. These proteins are called biomarkers due to five different reasons (1) These were found to be differentially expressed in PD-related microarray datasets (2) Proteins corresponding to these genes are the most topologically significant nodes (hubs and bottlenecks) in the protein-protein interaction networks (3) They showed significant involvement in the known complexes (4) They showed involvement with PD-associated neurotransmitters (5) These were not known previously to be associated with PD.

**Comparison with the study of Moran et al.**

Moran et al. reported several genes to be confirmed PD-associated sequences or a first PD expression signature [10]. A very important finding of this study concerned a series of 25 highly significant involvement in the known complexes (4) They showed involvement with PD-associated neurotransmitters (5) These were not known previously to be associated with PD.

### Table 17. Co-expression level of significant disease markers in core functional modules.

| *N*<sub>core</sub> -contained core functional module | Hubs | Interacting partners | Control* | Disease* |
|--------------------------------------------------|------|----------------------|----------|----------|
| ACTB                                             | TJP2 | 0                    | −0.33    |          |
|                                                 | VCL  | −0.2                 | 0.13     |          |
|                                                 | RPLP0| −0.21                | 0.18     |          |
|                                                 | ANXA2| −0.47                | 0.03     |          |
|                                                 | ARPC1B| −0.38                | 0.03     |          |
|                                                 | HSPA1B| 0.43                 | −0.28    |          |
| ACTG1                                            | NF2  | −0.12                | 0.03     |          |
|                                                 | MAP3K7IP2| −0.31                 | 0        |          |
|                                                 | VCL  | −0.27                | 0.2      |          |
|                                                 | IQGAP1| 0                    | −0.2     |          |
|                                                 | VASP | 0.03                 | −0.16    |          |
|                                                 | SPTBN1| 0.24                | −0.19    |          |
|                                                 | TJP2  | −0.15                | 0.05     |          |
|                                                 | ARPC1B| −0.33                | 0.14     |          |

| Bottlenecks                                      | Interacting partners | Control* | Disease* |
|--------------------------------------------------|----------------------|----------|----------|
| CTNNA1                                           | VCL                  | 0.14     | −0.06    |
|                                                 | SPTBN1               | −0.2     | 0.03     |
| GSN                                              | ACTB                 | 0.16     | −0.23    |
|                                                 | VASP                 | 0.41     | −0.53    |

| *N*<sub>str</sub>-contained functional module | Hubs | Interacting partners | Control* | Disease* |
|-----------------------------------------------|------|----------------------|----------|----------|
| CSNK2A1                                        | YWHAB | 0.58                 | 0.03     |          |
|                                                 | SNCA  | 0.67                 | −0.1     |          |
| CLTC                                           | No significant co-expression change available |          |          |          |
| Bottlenecks                                    | Interacting partners | Control* | Disease* |
| PARD3                                          | No significant co-expression change available |          |          |          |
| IqGAP1                                         | YWHAZ | −0.39                | 0.25     |          |

*Here the co-expression values are rounded up to the second decimal place.

doi:10.1371/journal.pone.0103047.t017

### Table 18. Involvement of unreported disease markers (in *N*<sub>str</sub>) with neurotransmitters.

| Dopaminergic | Cholinergic | Serotonergic | Adrenergic | Glutamatergic | GABAergic |
|--------------|-------------|--------------|------------|---------------|-----------|
| ARRB2        | + [40,41]   | –            | + [42]     | –             | –         |
| STX1A        | + [43]      | –            | + [44,45,46]| –             | + [47]    |
| TFRC         | + [48]      | –            | –          | –             | + [47]    |
| MARCKS       | + [49]      | –            | + [50]     | + [50,51]     | + [52]    |

*+ indicates association. – indicates no association. Corresponding references for association are shown within third brackets.

doi:10.1371/journal.pone.0103047.t018
DE sequences which map to known PARK loci. It was proposed in their study that these 25 sequences represented candidates for as yet unidentified disease-causing genes. Interestingly, results of our study had very little overlap with their outcomes. Out of the 25 sequences reported in their study, only 1 was common to the data study had very little overlap with their outcomes. Out of the 25 DE sequences which map to known PARK loci. It was proposed in our study were found to contain most of the topologically significant nodes of the networks which acted as a significant node: as a hub in $N^A_{SAM}$ and as a bottleneck in $N^B_{SAM}$. Here it is interesting to note that CDC42 was recently proposed in a PPI network-based study to play critical roles in PD [53].

However, one should keep in mind that these studies had different goals. Hence the difference in the final outcomes is quite obvious. Also, this study takes into account an extensive statistical, topological and functional analysis to determine significant disease markers which was not performed in the previous study.

**Limitations**

Genes2FANs combines protein interaction data from DIP [54], MINT [55], BIND [56], HPRD [57], BioGRID [58], InmateDB [59], KEGG [60], IntAct [61], PPID [62], Ma’ayan et al. [63], Stelzl et al. [64], Rual et al. [65] and Yu et al. [66]. Similarly, POINc1 combines protein interaction data from DIP, MINT, BIND, HPRD, BioGRID, IntAct, MIPS [67], CYGD [68] and MPact [69]. Hence, by the merger of QQPPI networks formed by both Genes2FANs and POINc1, it was possible to access PPI data from all of these 14 databases in this study. Any insufficient and non-updated information in the databases will have an effect on our results. To minimize this error, we performed our studies using the information of the above mentioned databases updated till May, 2014. However information in most of the databases is incomplete. Hence, markers whose PPI data were not included in the databases in the above mentioned open source databases could not be included in this study.

Furthermore, the incompleteness of the human interactome could lead to data insufficiency, resulting in biased topological analyses. In this study, the PPI networks were constructed based on the assumption that the expression level of most of the proteins and mRNAs were positively correlated, but this might not be true for all cases. Furthermore, due to post-transcriptional and translational regulations, the correspondence between expression of a gene and its protein is complicated. It was not possible to incorporate protein expression in our study.

**Conclusion**

Differentially expressed genes in post-mortem brain samples of patients with PD have been identified in this study. Gene expression data and PPI data were used for topological analyses of protein-protein interactions for PD. Two sets of DE genes were selected from the microarray data separately using 2-tailed $t$-tests and SAM. These two sets of DE genes were run separately to construct QQPPI networks. Several important topologically significant nodes e.g., hubs and bottlenecks were identified as biologically significant nodes in the network, as it has already been established that hubs and bottlenecks correspond to biologically significant proteins with respect to the disease. With this approach, we have identified 37 proteins in our QQPPI networks which were not previously known to be associated with PD. Three and four-cliques were identified in the QQPPI networks. These cliques contain most of the topologically significant nodes of the networks which form core functional modules consisting of tightly-knitted sub-networks. Several cliques identified in our study were found to be involved in already known protein complexes associated with many biological processes. Out of the 37 markers, eight (CSNK2A1, CLTC, PARD3, IQGAP1, ACTB, ACTG1, CTNNNA1 and GSN) were significantly involved in the core functional modules and showed significant change in co-expression levels between disease and control state. Furthermore, proteins encoded by 4 genes (ARRB2, STX1A, TFFC, MARCKS) showed involvement with several neurotransmitters including dopamine, which plays a significant role in PD. These 12 proteins may be considered as biologically significant with respect to PD. Our study represents a novel investigation of the PPI networks for PD. The 37 network biomarkers identified in our study may provide as potential therapeutic targets for PD applications developments.

**Supporting Information**

Figure S1 QQPPI network built from the dataset obtained using 2-tailed $t$-test (P<0.05) (GeneChip B). Orange coloured square nodes represent hubs (HC nodes). Yellow coloured triangular nodes represent bottlenecks (bottlenecks). The core functional module containing 3,4-cliques are represented using blue coloured edges. Non-hub non-bottleneck nodes are coloured green if they are directly connected to a hub or a bottleneck, and grey otherwise. Inset: Subset of the QQPPI network containing hubs and bottlenecks only. (JPG)

Table S1 Topological properties of $N^A_{SAM}$. The table contains all nodes, hubs and bottlenecks in $N^A_{SAM}$ along with their topological properties according to tYNA. (XLSX)

Table S2 Topological properties of $N^A_{SAM}$. The table contains all nodes, hubs and bottlenecks in $N^A_{SAM}$ along with their topological properties according to tYNA. (XLSX)

Table S3 Topological properties of $N^B_{SAM}$. The table contains all nodes, hubs and bottlenecks in $N^B_{SAM}$ along with their topological properties according to tYNA. (XLSX)

Table S4 Properties of nodes in core functional modules. The table contains nodes in the core functional modules detected in $N^A_{2m}$, $N^A_{SAM}$ and $N^B_{2m}$ along with their degree, betweenness score and the number of their occurrences in 3- and 4-cliques. (XLSX)

Table S5 Co-expression table for proteins interacting within the core functional module in $N^A_{SAM}$. This table contains the interactions within the core functional module in the network $N^A_{2m}$, along with their Pearson correlation coefficients ($\rho$) in control (C) and disease (D) samples, net difference of $\rho$ in control and disease samples (C-D) and their percentage of maximum possible change from control to disease, expressed as $\frac{[(C-D)/\max(C-D)] * 100}{}$. Here, max (C-D) is 2 as $\rho$ lies within the closed interval $[-1, 1]$. (XLSX)

Table S6 Co-expression table for proteins interacting within the core functional module in $N^A_{SAM}$. This table contains the interactions within the core functional module in the network $N^A_{SAM}$, along with their Pearson correlation coefficients ($\rho$) in control (C) and disease (D) samples, net difference of $\rho$ in control and disease samples (C-D) and their percentage of maximum possible change from control to disease, expressed as

PLOS ONE | www.plosone.org 15 August 2014 | Volume 9 | Issue 8 | e103047
Network contains the interactions within the core functional module in control (C) and disease (D) samples, net difference of \((C-D)/\max(C-D) \times 100\). Here, \(\max(C-D) = 2\) as Table S7 Co-expression table for proteins interacting \((C-D)/\max(C-D) \times 100\). Here, \(\max(C-D) = 2\) as Table S8.

File S1 Clique finding procedure. The file contains the complete procedure, including the algorithm developed by us, which we have used to detect 3- and 4-cliques in the QQPPI networks.

(DOCX)

References

1. Pankratz ND, Wojciech J, Foroud T (2004) Parkinson Disease Overview. National (WA): University of Washington, Seattle. http://www.ncbi.nlm.nih.gov/books/NBK12237.
2. Samii A, Nott JG, Ransoms BR (2004) Parkinson's disease. Lancet 363 (9423): 1783-93.
3. Davie CA (2008) A review of Parkinson's disease. Br Med Bull 86 (1): 109-27.
4. Lesage S, Brice A (2009) Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18 (R1): R48-59.
5. Barabasi AL, Oltvai ZN (2004). Network biology: understanding the cell's functional organization. Nat Rev Genet 5(2): 101-113.
6. Tian C, Niu-chung W, Ha-zhen L, Liu Y, Hong-jin P, et al. (2009) Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 27(2):199-204.
7. Lee SA, Tiao TT, Yang KC, Lin H, Kuo YL, et al. (2011) Construction and analysis of the protein-protein interaction networks for schizophrenia, bipolar disorder, and major depression. BMC Bioinformatics 12 (Suppl 1):S20.
8. Ran J, Li H, Fu J, Liu L, Xing Y, et al. (2013) Construction and analysis of the protein-protein network interaction network related to essential hypertension. BMC Systems Biology 7:3.
9. Wu Z, Lizarrary RA, Gentleman R, Martinez-Murillo F, Spencer F (2004) A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. Journal of the American Statistical Association vol 99 page 909-917.
10. Moran LB, Diuk DC, Deprez M, Dexter DT, Pearce RK, et al. (2006) Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 7(1):1-11.
11. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121.
12. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA (2003) Identifying Biological Themes within Lists of Genes with EASE. Genome Biology 4(10):R70.
13. Medina I, Carbonell J, Pulido L, Madeira SC, Goetz S, et al. (2010) Babalomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling. Nucleic Acids Res 38:W210-3.
14. Al-Shahrour F, Minguez P, Tarraga J, Medina I, Alloza E, et al. (2007) FanGO+: a functional profiling tool for genomic data. Integration of functional annotation, regulatory motif and interaction data with microarray experiments. Nucleic Acids Res 35:W91-6.
15. Kancheva M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27-30.
16. Dannerferler R, Clark NR, Ma’ayan A (2012) Gene2Function: connecting genes through functional association networks. BMC Bioinformatics 13:156.
17. Lee SA, Chan CH, Chen TC, Yang CY, Huang KC, et al. (2009) POINeT: protein interactome with sub-network analysis and hub prioritization. BMC Bioinformatics 10:114.
18. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–504.
19. Becker MF, Rojas I (2001) A graph layout algorithm for drawing metabolic pathways. Bioinformatics 17(5): 461-7.
20. Yip KY, Yu H, Kim PM, Schultz M, Gerstein M (2006) The cYNA platform for comparative interactomics: a web tool for managing, comparing and mining multiple networks. Bioinformatics 22(23):2960-70.
21. Ray M, Ruan J, Zhang W (2008) Variations in the transcriptome of Alzheimer’s disease reveal molecular networks involved in cardiovascular diseases. Genome Biol 9(10):R148.
22. Ruepp A, Waegele B, Lehner B, Bauer D, Dengler-Kaltenbach I, et al. (2009) CORUM: a comprehensive resource of mammalian protein complexes—2009. Nucleic Acids Res 38:D497-501.
23. Barone P (2010) Neurotransmission in Parkinson's disease: beyond dopamine. European Journal of Neurology 17 (3): 364-376.
24. Dimitriou A, Latsourelle JC, Hadji TC, Pankratz N, Garza D, et al. (2012) Gene Expression Profiles in Parkinson Disease prefrontal cortex implicate FOXO1 and genes under its transcriptional regulation. PLoS Genet 8(6): e1002794.
25. Ferrer I, Martinez A, Blanco R, Dalfio E, Carmona M (2011) Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 118(3): 821-839.
26. Gomez A, Ferrer I (2010) Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol 120(2):155-67.
27. Cha G, Narasimhan B, Tibshirani R, Tusher V, SAM “Significance Analysis of Microarrays” Users Guide and technical document.
28. Chatterjee P, Bhattacharyya M, Bandopadhyay S, Roy D (2014) Studying the System-Level Involvement of MicroRNAs in Parkinson’s Disease. PLoS ONE 9(4): e93574.
29. Batada NN, Hurst LD and Tyers M (2006) Evolutionary and physiological importance of hub proteins. PLoS Comput Biol 2(7): e80.
30. Coulomb S, Bauer M, Bernard D, Marschner-Kogert MC (2005) Gene essentiality and the topology of protein interaction networks. Proc Biol Sci 272(1573): 1721-1725.
31. He X, Zhang J (2006) Why do hubs tend to be essential in protein networks? PLoS Genet 2(1):e50.
32. Friedel CC and Zimmer R (2007) Influence of degree correlations on network structure and stability in protein-protein interaction networks. BMC Bioinformatics 8:297.
33. Goel J, Etehadj FJ, de Mendizabal NV, Sepulcre J, Ardanza-Trevijano S, et al. (2008) A computational analysis of protein-protein interaction networks in neurodegenerative diseases. BMC Systems Biology 2:52.
34. Joy MP, Brock A, Inger DE, Hwang S (2005) High-betweenness proteins in the yeast protein interaction network. J Biomed Biotechnol 2, 96–103.
35. Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M (2007) The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 3(4): e39.
36. Gursoy A, Keskin O, Nussinov R (2008) Topological properties of protein interaction networks from a structural perspective. Biochem Soc Trans 36(Pt 6): 1398-1403.
37. Chen TC, Lee SA, Chan CH, Juang YL, Hong YK, et al. (2009) Clues in misconceptions of protein interaction networks bring kinesin-like-associated complexes to form dependence pathway. Proteomics 9(16):4048-4062.
38. Shin Y, Mirny LA (2003) Protein complexes and functional modules in molecular networks. Proc Natl Acad Sci USA 100 (21):12125-12128.
39. Wall DP, Provazerov R, Tong MJ, Jung YJ, Fusaro VA, et al. (2010) Genotator: A disease-agnostic tool for genetic annotation of disease. BMC Medical Genomics 3:50.
40. Kim SJ, Sung JY, Um JW, Hattori N, Mizuno Y, et al. (2003) Parkin cleaves intracellular alpha-Synuclein inclusions via the activation of calpain. J Biol Chem 278(43): 41890-41899.
41. Borjik K, Tronci V, Thorsell A, Tanda G, Hirth N, et al. (2013) β-Arrestin 2 knockout mice exhibit sensitized dopamine release and increased reward in response to a low dose of alcohol. Psychopharmacology (Berl) 230(3):439-49.
42. Thuliah A, Horre K, Smelink A, Vandevelde E, Huang V, et al. (2013) β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer’s disease. Nat Med 19(1):43-9.
43. Mishima T, Fujiwara T, Kofuji T, Akagawa K (2012) Impairment of catecholamine systems during induction of long-term potentiation at hippocampal CA1 synapses in HPC-1/syntaxin 1A knock-out mice. J Neurosci 32(1):301–9.

44. Cervinski MA, Foster JD, Vaughan RA (2010) Syntaxin 1A regulates dopamine transporter activity, phosphorylation and surface expression. Neuroscience 170(2):454–8.

45. Nakamura K, Anitha A, Yamada K, Tsuji M, Iwayama Y, et al. (2008) Genetic and expression analyses reveal elevated expression of syntaxin 1A (STX1A) in high functioning autism. Int J Neuropsychopharmacol 11(8):1073–84.

46. Nakamura K, lwata Y, Anitha A, Miyachi T, Toyota T, et al. (2011) Replication study of Japanese cohorts supports the role of STX1A in autism susceptibility. Prog Neuropsychopharmacol Biol Psychiatry 35(2):454–8.

47. Bragina L, Giovedi S, Barbaresi P, Benfenati F, Conti F (2010) Heterogeneity of glutamatergic and GABAergic release machinery in cerebral cortex: analysis of synaptogyrin, vesicle-associated membrane protein, and syntaxin. Neuroscience 165(3):934–43.

48. Jellen LC, Lu L, Wang X, Unger EL, Earley CJ, et al. (2013) Iron deficiency alters expression of dopamine-related genes in the ventral midbrain in mice. Neuroscience 252:13–23.

49. Lu D, Yang H, Lenox RH, Raizada MK (1998) Regulation of angiotensin II-induced neuropeptide Y. Neuroscience 32(1):381–9.

50. Cervinski MA, Foster JD, Vaughan RA (2010) Syntaxin 1A regulates dopamine transporter activity, phosphorylation and surface expression. Neuroscience 170(2):408–16.

51. Nakamura K, Anitha A, Yamada K, Tsuji M, Iwayama Y, et al. (2008) Genetic and expression analyses reveal elevated expression of syntaxin 1A (STX1A) in high functioning autism. Int J Neuropsychopharmacol 11(8):1073–84.

52. Bragina L, Giovedi S, Barbaresi P, Benfenati F, Conti F (2010) Heterogeneity of glutamatergic and GABAergic release machinery in cerebral cortex: analysis of synaptogyrin, vesicle-associated membrane protein, and syntaxin. Neuroscience 165(3):934–43.

53. Jellen LC, Lu L, Wang X, Unger EL, Earley CJ, et al. (2013) Iron deficiency alters expression of dopamine-related genes in the ventral midbrain in mice. Neuroscience 252:13–23.

54. Lu D, Yang H, Lenox RH, Raizada MK (1998) Regulation of angiotensin II-induced neuropeptide Y. Neuroscience 32(1):381–9.

55. Cervinski MA, Foster JD, Vaughan RA (2010) Syntaxin 1A regulates dopamine transporter activity, phosphorylation and surface expression. Neuroscience 170(2):408–16.

56. Bader GD, Betel D, Hogue CW (2003) BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res 31(1):248–250.

57. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al. (2009) Human Protein Reference Database–2009 update. Nucleic Acids Res 37:D767–772.

58. Stahl C, Bader GD, Betel D, Hogue CW (2003) BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res 31(1):248–250.

59. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al. (2009) Human Protein Reference Database–2009 update. Nucleic Acids Res 37:D767–772.

60. Stahl C, Bader GD, Betel D, Hogue CW (2003) BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res 31(1):248–250.